Clinical pharmacist assessment of drug-related problems among intensive care unit patients in a Turkish university hospital

Abstract

Background Critically ill patients treated in the intensive care units (ICUs) often suffer from side effects and drug-related problems (DRPs) that can be life-threatening. A way to prevent DRPs and improve drug safety and efficacy is to include clinical pharmacists in the clinical team. This study aims to evaluate the classification of drug-related problems and the implementation of clinical pharmacy services by a clinical pharmacist in the ICU of a university hospital in Turkey. Methods This study was carried out prospectively between December 2020 and July 2021 in Gazi University Medical Faculty Hospital Internal Diseases ICU. All patients hospitalized in the intensive care unit for more than 24 h were included in the study. During the study, the clinical pharmacist's interventions and other clinical services for patients were recorded. DRPs were classed according to the Pharmaceutical Care Network Europe V.8.02. Results A total of 151 patients were included during the study period corresponding to 2264 patient-days. Patients with DRPs had a longer hospital stay and a higher mortality rate (p < 0.05). 108 patients had at least one DRP and the total number of DRPs was 206. There was an average of 1.36 DRPs per patient, 71.5% of patients experienced DRP and 89.22 DRPs per 1000 patient-days. A total of 35 ADEs were observed in 32 patients. ADE incidence was per 1000 patient-days 15.45. ADEs were caused by nephrotoxicity (48.57%), electrolyte disorders (17.14%), drug-induced thrombocytopenia (17.14%), liver enzyme increase (8.57%) and other causes (8.57%). Drug selection (40.29%) and dose selection (54.36%) constituted most of the causes of DRPs. Dose change was the highest percentage of planned interventions with a rate of 56.79%. Intervention was accepted at a rate of 90.8% and it was fully implemented. Conclusion In this study, the importance of the clinical pharmacist in the determination and analysis of DRPs was emphasized. Clinical pharmacy services like the one described should be implemented widely to increase patient safety.

Improving Antibiotic Use in Surgical Care: Impact of Clinical Pharmacist Interventions on Optimizing Patient Therapy

“…The acceptance rate of pharmacist interventions was 99%, and as a result, there was a change in https://www.indjst.org/ drug therapy as per pharmacist recommendations. This acceptance rate was higher than in previous studies in China, Ethiopia, Japan, and Turkey (1,(14)(15)(16) . This might be due to a well-established clinical pharmacy facility with a full-time clinical pharmacist exclusively dedicated to the Surgery ward to provide clinical pharmacy services at the bedside as tailored recommendations in real-time by considering the patient's condition and closely associating and understanding the various concerns of surgeons.…”

Interventions and Impact of Pharmacist-Delivered Services for People Infected with COVID-19: A Systematic Review

“…These results are also well supported by the studies of Wang et al and Rodriguez et al [ 42 , 53 ]. Review findings reported pharmacists regularly monitored the records of patients admitted to ICUs, reviewed their prescriptions and lab reports, managed their medication errors and did interventions to balance their electrolytes and these findings were supported by the literature [ 54 , 55 , 56 , 57 , 58 , 59 ].…”

Potenciais eventos adversos a medicamentos: coorte em unidades de terapia intensiva

“…O acompanhamento do paciente ocorreu do dia de admissão até a saída Medicina (Ribeirão Preto) 2022;55(3):e-197132 da UTI -por alta ou óbito. Para cálculo amostral, utilizou-se o total de internações nas UTIs dos últimos doze meses, uma frequência de ocorrência de EAM de aproximadamente 13% 4,7,16,20,23,24 , perdas de 10% e erro de 5%; assim o cálculo indicou um tamanho amostral mínimo de 83 participantes.…”